Bicistronic AAV Vector for ALS Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for treating motoneuron diseases like ALS require multiple viral vectors to target both astrocytes and motoneurons, which face limitations in viral load, volume restrictions, and increased immune reactions, making them unsuitable for clinical use.
Innovation Solution
A bicistronic expression vector is developed, comprising two expression cassettes with astrocyte and neuron-specific promoters, along with SOD1 silencer sequences, allowing simultaneous and specific silencing of the SOD1 gene in both cell types using a single vector, thereby overcoming the need for multiple injections and reducing regulatory hurdles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple viral vectors are used to target both astrocytes and motoneurons, then gene delivery coverage is improved, but device complexity and immune reaction risk increase
Solution Approach 1:
The patent combines two separate viral vectors into a single bicistronic AAV vector that expresses both GFAP-siRNA (for astrocytes) and synapsin-siRNA (for motoneurons). This merging approach maintains the ability to target both cell types while reducing the complexity of administering and managing multiple separate vectors, thereby resolving the contradiction between delivery coverage and system complexity.
Solution Approach 2:
The bicistronic vector serves multiple functions simultaneously: it delivers silencer sequences to both astrocytes and motoneurons, expresses two different siRNAs from a single construct, and reduces the number of injections required. This multi-functionality allows one vector to perform the work previously requiring multiple vectors, addressing both coverage and complexity concerns.
2Adaptability or versatility
If multiple viral vectors are administered, then transduction of multiple cell types is improved, but volume restrictions and injection limitations worsen
Solution Approach 1:
By merging the silencer sequences for both astrocytes and motoneurons into a single bicistronic vector construct, the total injection volume is reduced. Instead of administering two separate vectors that would each require their own volume, the combined vector delivers both therapeutic functions in one injection, directly addressing the volume restriction problem.
3Reliability
If multiple viral vectors are used, then therapeutic coverage is improved, but immune reaction risk increases
Solution Approach 1:
The patent merges multiple vector administrations into a single injection event. By consolidating the delivery of silencer sequences for both astrocytes and motoneurons into one bicistronic vector, the number of times the immune system is exposed to foreign viral particles is reduced, thereby lowering the cumulative immune reaction risk while maintaining comprehensive therapeutic coverage.
4Manufacturing precision
If separate vectors are used for astrocytes and motoneurons, then cell-specific targeting is improved, but regulatory complexity increases
Solution Approach 1:
The patent combines cell-specific targeting capabilities for both astrocytes and motoneurons into a single regulatory framework. Instead of requiring separate approvals for multiple vectors, the bicistronic construct is evaluated as one therapeutic product, simplifying the regulatory pathway while maintaining the precision of cell-specific silencing through promoter-driven expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bicistronic vector achieves enhanced therapeutic efficacy by prolonging survival and preserving neuromuscular function in ALS models, with improved safety by minimizing off-target effects and maximizing transduction efficiency, demonstrating superior performance compared to single-expression cassette vectors.
Implementation Method 1
The first expression cassette comprises 'astrocyte specific promoter - posttranscriptional regulatory element - a first SOD1 silencer sequence'
Implementation Method 2
the second expression cassette comprises 'neuron specific promoter - posttranscriptional regulatory element - a second SOD1 silencer sequence'
Implementation Method 3
Bicistronic AAV vector for RNA interference in als
Data Source
Figure 1A~1D
Figure 2
Figure 3(A)~3(B)
AI summary
The present invention relates to a bicistronic expression vector for silencing a gene specifically in astrocytes and neurons, comprising two expression cassettes comprising a first and a second silencer sequence, respectively, wherein the expression of said first silencer sequence within astrocytes is regulated by an astrocyte-specific promoter and the expression of said second silencer sequence within neurons is regulated by a neuron-specific promoter. In a preferred embodiment, said first and second silencer sequences are SOD1 silencer sequences. Pharmaceutical composition comprising said bicistronic vector and the use of the same in the treatment of motoneuron diseases are further described.